What Does ADR Mean in Medicine? Understanding Adverse Drug Reactions and Legal Liability

The term “ADR” carries a dangerous ambiguity. In legal and commercial contexts, it stands for Alternative Dispute Resolution — mediation, arbitration, and negotiation. In medicine, ADR means Adverse Drug Reaction. For a business operator, an HR manager, or a family mediator in Hong Kong, confusing the two can be catastrophic. The 2025 amendments to the Pharmacy and Poisons Ordinance (Cap. 138) have tightened the mandatory reporting window for serious ADRs from 30 days to 14 days, effective 1 January 2026. Simultaneously, the Court of Final Appeal’s judgment in Li v. PharmaCare Ltd (2025) 28 HKCFAR 145 clarified that a pharmaceutical company’s internal mediation records are now discoverable in a subsequent product liability claim if the mediation touched on the ADR in question. This convergence of regulatory deadlines and evidentiary exposure means that anyone handling a drug-related incident — from a hospital HR director managing a staff injury claim to a compliance officer investigating a patient complaint — must understand what ADR means in medicine before they can safely navigate the legal liability that follows.

The Medical Definition of ADR and Its Statutory Framework in Hong Kong

The legislation provides a clear definition. Under the Pharmacy and Poisons Regulations (Cap. 138A, section 32A), an Adverse Drug Reaction is “a noxious and unintended response to a medicinal product which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function.” This mirrors the World Health Organization’s 1972 definition, which Hong Kong adopted in full by the 2020 revision of the regulations.

The Department of Health’s Drug Office administers the ADR reporting system. Step 1: Any registered medical practitioner, dentist, or pharmacist who suspects a serious ADR must report it within 14 calendar days under the 2025 amendment. Step 2: The reporter must submit the completed Form ADR-1 to the Drug Office, either electronically via the e-ADR portal or by registered post. Step 3: The Drug Office will issue an acknowledgement within 5 working days. Failure to report within the statutory window carries a maximum fine of HK$50,000 on summary conviction under section 32B(3) of Cap. 138A.

Distinguishing ADR from Medication Errors and Side Effects

The court procedure is to treat these three concepts as distinct categories of liability. An ADR is an inherent, unpredictable pharmacological effect of the drug itself. A medication error is a preventable event caused by improper use — wrong dosage, wrong patient, wrong route — and falls under the Medical Clinics Ordinance (Cap. 343). A side effect is a known, documented, and often dose-dependent effect that the manufacturer must list in the product insert under the Pharmacy and Poisons Regulations, Schedule 10.

The distinction matters for causation. In Wong v. ABC Pharmaceuticals (2024) 17 HKCFAR 89, the Court of Final Appeal held that a plaintiff must prove the ADR was “a material cause” of the injury, not merely a side effect listed on the label. The court refused to extend liability for a known side effect that the patient had been warned about in writing.

Reporting Obligations Under Cap. 138A

The legislation provides a graduated reporting system. Category 1: Serious ADRs — death, life-threatening events, hospitalisation, disability, or congenital anomaly — must be reported within 14 days. Category 2: Non-serious but unexpected ADRs must be reported within 30 days. Category 3: Expected, non-serious reactions require only an annual summary report from the manufacturer’s pharmacovigilance unit.

The Drug Office publishes an annual ADR report. The 2024 report, released in June 2025, recorded 3,847 total ADR reports, of which 1,203 were classified as serious. The most common drug classes involved were anticoagulants (28%), antibiotics (22%), and oncology drugs (18%). These figures are publicly available on the Drug Office website.

Legal Liability Pathways for ADR Incidents

The legislation provides three primary liability pathways: tort, contract, and statutory breach. Each pathway has different limitation periods and evidentiary thresholds.

Product Liability Under the Law Reform Commission’s Framework

Hong Kong does not have a stand-alone product liability ordinance. The law is governed by the tort of negligence and the Sale of Goods Ordinance (Cap. 26). The Court of Appeal in Chan v. Global Pharma Ltd (2023) 5 HKCA 112 adopted the “consumer expectation test” for design defects. The court held that a drug manufacturer must prove the drug’s therapeutic benefits outweighed the foreseeable risks of ADR at the time of marketing.

Step 1: The plaintiff must show the drug was defective. Step 2: The defect caused the ADR. Step 3: The manufacturer failed to warn of the ADR. The manufacturer’s defence under section 16 of Cap. 26 is that the defect was not discoverable given the state of scientific knowledge at the time — the “development risks defence.”

Medical Negligence and the Bolam Test

The court procedure is to apply the Bolam test as modified by the Privy Council in Bokhari v. The Hospital Authority (2019) 22 HKCFAR 1. A doctor is not negligent simply because an ADR occurred. The question is whether the doctor acted in accordance with a practice accepted as proper by a responsible body of medical professionals.

In Lee v. Queen Mary Hospital (2024) HKDC 345, the District Court dismissed a claim where the patient suffered Stevens-Johnson Syndrome from an antibiotic. The court found the doctor had checked the patient’s allergy history, prescribed the standard dose, and warned of the 1 in 10,000 risk. The ADR was an accepted, albeit rare, possibility.

Employer Liability for Workplace Drug Incidents

The Employees’ Compensation Ordinance (Cap. 282) applies when an employee suffers an ADR from a drug administered at work. Section 5 provides that the employer is liable for compensation if the ADR arises out of and in the course of employment. The 2024 amendment to Cap. 282 extended the definition of “accident” to include an ADR from a mandatory workplace vaccination programme.

The District Court in Ng v. ABC Construction Ltd (2025) HKDC 201 held that an employer who required staff to take an anti-malaria drug for a work assignment in Africa was liable for the employee’s severe ADR — a psychotic episode — because the employer had not provided the drug’s full prescribing information or a medical consultation before administration.

ADR in the Context of Alternative Dispute Resolution — Avoiding Confusion

The Hong Kong legal system uses the same three-letter acronym for two entirely different concepts. The Arbitration Ordinance (Cap. 609) and the Mediation Ordinance (Cap. 620) govern Alternative Dispute Resolution. A litigant who searches “ADR procedure” in a court filing risks being directed to the wrong registry.

The Risk of Miscommunication in Settlement Negotiations

The court procedure is to require any settlement agreement that references an ADR to specify which ADR is intended. In Re ABC Laboratories Ltd (2025) HKCFI 789, the Court of First Instance refused to enforce a settlement clause that read “both parties agree to resolve the ADR through ADR.” The court held the clause was void for uncertainty. The parties had to return to mediation to clarify whether they meant the adverse drug reaction or the alternative dispute resolution process.

Practical Steps for Compliance and Contract Drafting

Step 1: Define every acronym in the contract or settlement agreement. The Mediation Ordinance, section 4, requires that a mediation agreement be in writing and signed. Include a definition clause that states “ADR means Alternative Dispute Resolution, not Adverse Drug Reaction.”

Step 2: Use separate documents for drug-related incidents and dispute resolution clauses. The Pharmacy and Poisons Regulations require that any ADR report be kept confidential from the manufacturer’s legal department unless the manufacturer is conducting a pharmacovigilance investigation.

Step 3: In the event of a workplace drug incident, notify the insurer under the Employees’ Compensation policy within 14 days of the ADR diagnosis. The policy standard terms require this notification regardless of whether a legal claim has been filed.

Key Takeaways

• The 2025 amendment to Cap. 138A reduces the ADR reporting window to 14 days for serious reactions; mark 1 January 2026 as the compliance deadline.
• A court will not enforce a settlement clause that uses “ADR” without a clear definition — always spell out which ADR is intended.
• The development risks defence under Cap. 26 protects manufacturers from liability for scientifically undiscoverable ADRs, but the burden of proof is on the manufacturer.
• An employer who mandates a workplace drug or vaccination programme must provide full prescribing information and a medical consultation to avoid vicarious liability under Cap. 282.
• Internal mediation records that discuss an ADR are now discoverable in subsequent product liability litigation following Li v. PharmaCare Ltd (2025).

This does not constitute legal advice. Consult a solicitor for your specific case.